Pregnancy and Pulmonary Hypertension

Heart Disease in Pregnancy: Second Edition

Volumn , Issue , 2007, Pages 59-78

  Parambil, Joseph G ^a   McGoon, Michael D ^b  

^a CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

^b Mayo Clinic College of Medicine   (United States)

Author keywords

Chest radiograph; Pregnancy; Pulmonary arterial hypertension (PAH); Pulmonary capillary wedge pressure (PCWP); Pulmonary hypertension (PH)

Indexed keywords

EID: 62649102187     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470994955.ch6     Document Type: Chapter

References (54)

1. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med 1987;107:216-23.
2. McGoon MD, Gutterman D, Steen V, et al. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004;126(suppl 1):14S-34S.
3. Barst RJ, McGoon MD, Torbicki A, et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43(suppl 12):S40-7.
4. Simonneau G, Galiè N, Rubin L, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004;43(suppl 12):S5-12.
5. Voelkel NF, Cool C. Pathology of pulmonary hypertension. Cardiol Clin 2004;22: 343-51.
6. Gomez A, Bialostozky D, Zajarias A, et al. Right ventricular ischemia in patients with primary pulmonary hypertension. J Am Coll Cardiol 2001;38:1137-42.
7. Kawut S, F. S, Ferrari V, et al. Extrinsic compression of the left main coronary artery by the pulmonary artery in patients with long-standing pulmonary hypertension. Am J Cardiol 1999;83:984-6.
8. Mesquita S, Castro C, Ikari N, Oliveira S, Lopes A. Likelihood of left main coronary artery compression based on pulmonary trunk diameter in patients with pulmonary hypertension. Am J Med 2004;116:369-74.
9. Rich S, McLaughlin VV, O'Neill W. Stenting to reverse left ventricular ischemia due to left main coronary artery compression in primary pulmonary hypertension. Chest 2001;120:1412-15.
10. Bonderman D, Fleischmann D, Prokop M, Klepetko W, Lang IM. Left main coronary artery compression by the pulmonary trunk in pulmonary hypertension. Circulation 2002;105:265.
11. Parish JM, Somers VK. Obstructive sleep apnea and cardiovascular disease. Mayo Clinic Proc 2004;79:1036-46.
12. Loyd JE. Genetics and gene expression in pulmonary hypertension. Chest 2002;121:46S-50S.
13. Deng Z, Morse JH, Slager SL, et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Human Genet 2000;67(electronically published).
14. Abenhaim L, Moride Y, Brenot F, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 1996;335:609-16.
15. Mesa R, Edell E, Dunn WF, W. E. Human immunodeficiency virus infection and pulmonary hypertension: two new cases and a review of 86 reported cases. Mayo Clinic Proc 1998;73:37-45.
16. Currie PJ, Seward JB, Chan KL. Continuous wave Doppler determination of right ventricular pressure: a simultaneous Doppler-catheterization study in 127 patients. J Am Coll Cardiol 1985;6:750-6.
17. Ommen SR, Nishimura RA, Hurrell DG, Klarich KW. Assessment of right atrial pressure with 2-dimensional and Doppler echocardiography: a simultaneous catheterization and echocardiographic study. Mayo Clinic Proc 2000;75:24-9.
18. Miyamoto S, Nagaya N, Satoh T, et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension: comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 2000;161:487-92.
19. Badesch DB, Abman SH, Ahearn GS, et al. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004; 126(suppl 1):35S-62S.
20. Sitbon O, Humbert M, Jais X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005;111:3105-11.
21. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002;40:780-8.
22. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002;106:1477-82.
23. Barst RJ, Rubin LJ, McGoon MD, Caldwell EJ, Long WA, Levy PS. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 1994;121:409-15.
24. McLaughlin VV, Gaine SP, Barst RJ, et al. Efficacy and safety of treprostinil: an epoprostenol analogue for primary pulmonary hypertension. J Cardiovasc Pharmacol 2003;41:293-9.
25. Oudiz R, Schilz RJ, Barst RJ, et al. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. Chest 2004;126: 420-7.
26. Olschewski H, Simonneau G, Galie N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002;347:322-9.
27. Ghofrani HA, Rose F, Schermuly RT, et al. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol 2003;42:158-64.
28. Wilkens H, Guth A, Konig J, et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 2001;104:1218-22.
29. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001;358:1119-23.
30. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903.
31. Sitbon O, Badesch DB, Channick RN, et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year followup study. Chest 2003;124:247-54.
32. Paul GA, Gibbs JS, Boobis AR, Abbas AE, Wilkins MR. Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. Br J Clin Pharmacol 2005;60:107-12.
33. Galie N, Ghofrani A, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353(20):2148-57.
34. Fuster V, Frye RL, Gersh BJ, McGoon MD, Steele PM. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 1984;70: 580-7.
35. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992;327:76-81.
36. Crapo RO. Normal cardiopulmonary physiology during pregnancy. Clin Obstet Gynecol 1996;39:3-16.
37. Oakley CM. Cardiovascular disease in pregnancy. Can J Cardiol 1990;6:3-9.
38. Weiss BM, Zemp L, Seifert B, Hess OM. Outcome of pulmonary vascular disease in pregnancy: a systematic overview from 1978 through 1996. J Am Coll Cardiol 1998;31:1650-7.
39. Gleicher G, Midwall J, Hochberger D, Jaffin H. Eisenmenger's syndrome and pregnancy. Obstet Gynecol 1979;34:721-41.
40. Weiss B, Hess OM. Pulmonary vascular disease and pregnancy: current controversies, management strategies, and perspectives. Eur Heart J 2000;21:104-15.
41. Rout CC. Anesthesia and analgesia for the critically ill parturient. Best Pract Res Clin Obstet Gynecol 2001;15:507-22.
42. Duggan AB, Katz SG. Combined spinal and epidural anesthesia for cesarean section in a parturient with severe primary pulmonary hypertension. Anesth Intens Care 2003;31:565-9.
43. Bonnin M, Mercier FJ, Sitbon O, et al. Severe pulmonary hypertension during pregnancy. Anesthesiology 2005;102:1133-7.
44. Avila WS, Grinberg M, Snitcowsky R, Faccioli R, Da Luz PL, Pileggi F. Maternal and fetal outcome in pregnant women with Eisenmenger's syndrome. Eur Heart J 1995;16(4):460-4.
45. Lacassie HJ, Germain AM, Valdes G, Fernandez MS, Allamand F, Lopez H. Management of Eisenmenger syndrome in pregnancy with sildenafil and L-arginine. Obstet Gynecol 2004;103(5 Pt 2):1118-20.
46. Goodwin TM, Gherman RB, Hameed A, Elkayam U. Favorable response of Eisenmenger syndrome to inhaled nitric oxide during pregnancy.[See comment.] Am J Obstet Gynecol 1999;180(1 Pt 1):64-7.
47. Lust KM, Boots RJ, Dooris M, Wilson J. Management of labour in Eisenmenger syndrome with inhaled nitric oxide. Am J Obstet Gynecol 1999;181:419-23.
48. Decoene C, Boursoufi K, Moreau D, Narducci F, Crepin F, Krivosic-Horber R. Use of inhaled nitric oxide for emergency cesarean section in a woman with unexpected primary pulmonary hypertension. Canadian J of Anesthesia 2001;48(6):584-7.
49. Avdalovic M, Sandrock C, Hoso A, Allen R, Albertson TE. Epoprostenol in pregnant patients with secondary pulmonary hypertension: two case reports and a review of the literature. Treatment Respir Med 2004;3(1):29-34.
50. Badalian SS, Silverman RK, Aubry RH, Longo J. Twin pregnancy in a woman on longterm epoprostenol therapy for primary pulmonary hypertension. A case report. J Reprod Med 2000;45(2):149-52.
51. Stewart R, Tuazon D, Olson G, Duarte AG. Pregnancy and primary pulmonary hypertension: successful outcome with epoprostenol therapy. Chest 2001;119:973-5.
52. Nootens M, Rich S. Successful management of labour and delivery in primary pulmonary hypertension. Am J Cardiol 1993;71:1124-5.
53. Torres PJ, Gratacos E, Magrina J, Martinez-Crespo JM. Primary pulmonary hypertension and pre-eclampsia: a successful pregnancy. Br J Obstet Gynaecol 1994;101: 163-5.
54. Blaise G, Langleben D, Hubert B. Pulmonary arterial hypertension: pathophysiology and anesthetic approach. Anesthesiology 2003;99:1415-32.